Form 4: Vericel Corp Executive Jonathan Siegal Executes Stock Option and Sells Shares

Vericel Corp's Principal Accounting Officer, Jonathan Siegal, exercised stock options and sold shares under a pre-arranged trading plan.

Summary

• Jonathan Siegal, Principal Accounting Officer at Vericel Corp, exercised stock options to acquire 3,908 shares of common stock at a price of $48.80 per share on January 28, 2025.
• On the same day, Siegal sold 3,908 shares of common stock at a price of $61.99 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 13, 2024.
• Following these transactions, Siegal directly owns 1,206 shares of common stock and 52,967 stock options.

Sentiment

Score: 5

Explanation: The document is a routine filing of insider trading activity, which is neither positive nor negative in itself. The transactions were pre-planned and expected.

Industry Context

This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a Rule 10b5-1 plan indicates a pre-planned strategy for trading company stock.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a common practice among executives at publicly traded companies like Vericel Corp to avoid accusations of insider trading.
• The vesting schedule of the stock options, with 25% vesting after one year and the remainder over three years, is a typical structure for employee stock options.
• Companies like Amgen, Biogen, and Regeneron also have executives who regularly file Form 4s for similar transactions.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan and do not indicate a change in the company's fundamentals.

Key Dates

Keywords

stock options, insider trading, Rule 10b5-1, share sale, executive compensation, Vericel Corp, VCEL